The computation of basic net income per share is based on the number of weighted average shares outstanding during the period. The computation of diluted net income per share includes the dilutive effect of share equivalents consisting of incremental shares deemed outstanding from the assumed exercise of options and unvested restricted stock units ("RSUs"). Performance share awards ("PSAs") are included in the computation of diluted net income per share only to the extent that the underlying performance conditions are

satisfied prior to the end of the reporting period or would be satisfied if the end of the reporting period were the end of the related performance period, and if the effect would be dilutive.

A reconciliation of the numerators and denominators of the basic and diluted net income per share calculations is as follows (in thousands, except per share amounts):


	Thirteen weeks ended				Thirty-nine weeks ended
	September 27, 2026		September 28, 2025		September 27, 2026		September 28, 2025
Basic net income per share:
Net income	$	113,421	$	120,116	$	406,340	$	433,845
Weighted average shares outstanding - basic	93,128		97,672		93,976		98,023
Basic net income per share	$	1.22	$	1.23	$	4.32	$	4.43
Diluted net income per share:
Net income	$	113,421	$	120,116	$	406,340	$	433,845
Weighted average shares outstanding - basic	93,128		97,672		93,976		98,023
Dilutive effect of share-based awards:
Assumed exercise of options to purchase shares	327		532		344		563
RSUs	105		237		123		330
PSAs	106		274		113		170
Weighted average shares and equivalent shares outstanding - diluted	93,666		98,715		94,556		99,086
Diluted net income per share	$	1.21	$	1.22	$	4.30	$	4.38

For the thirteen weeks ended September 27, 2026, the Company had 0.2 million options, 0.1 million RSUs and 0.1 million PSAs outstanding, which were excluded from the computation of diluted net income per share as those awards would have been antidilutive or were performance awards with performance conditions not yet deemed met. For the thirteen weeks ended September 28, 2025, the Company had 0.1 million options and 0.2 million PSAs outstanding, which were excluded from the computation of diluted net income per share as those awards would have been antidilutive or were performance awards with performance conditions not yet deemed met.

For the thirty-nine weeks ended September 27, 2026, the Company had 0.1 million options, 0.1 million RSUs and 0.1 million PSAs outstanding, which were excluded from the computation of diluted net income per share as those awards would have been antidilutive or were performance awards with performance conditions not yet deemed met. For the thirty-nine weeks ended September 28, 2025, the Company had 0.1 million options and 0.2 million PSAs outstanding, which were excluded from the computation of diluted net income per share as those awards would have been antidilutive or were performance awards with performance conditions not yet deemed met.